5759-63-7

Basic information

• Product Name: 3-Methyl-6-methylaminouracil
• Synonyms: 3-METHYL-6-METHYLAMINOURACIL;6-(METHYLAMINO)-3-METHYLURACIL;2,4(1H,3H)-Pyrimidinedione, 3-methyl-6-(methylamino)-;3-methyl-6-(methylamino)-1H-pyrimidine-2,4-dione
• CAS NO: 5759-63-7
• Molecular Formula: C₆H₉N₃O₂
• Molecular Weight: 155.15
• Mol File: 5759-63-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.3 g/cm³
• Refractive Index: 1.566
• CAS DataBase Reference: 3-Methyl-6-methylaminouracil(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Methyl-6-methylaminouracil(5759-63-7)
• EPA Substance Registry System: 3-Methyl-6-methylaminouracil(5759-63-7)

Safety Data

• Hazardous Substances Data: 5759-63-7(Hazardous Substances Data)

Usage

General Description

3-Methyl-6-methylaminouracil is a chemical compound that belongs to the class of uracil derivatives. It consists of a uracil core with an additional methyl group at the 3-position and a methylamino group at the 6-position. This chemical compound is used in the pharmaceutical industry as a building block for the synthesis of various drugs and pharmaceutical products. It has also been studied for its potential biological and pharmacological activities, including its role as an anti-cancer agent and its ability to modulate enzyme activity. Overall, 3-Methyl-6-methylaminouracil has potential applications in the development of new therapeutic agents and pharmaceuticals.

InChI:InChI=1/C6H9N3O2/c1-7-4-3-5(10)9(2)6(11)8-4/h3,7H,1-2H3,(H,8,11)

Upstream product

• 4318-56-3 3-methyl-6-chlorouracil 
• 74-89-5 methylamine 

Downstream Products

• 92978-47-7 3,8-Dimethyl-6-{phenyl-[(E)-(S)-1-phenyl-ethylimino]-methyl}-1H,8H-pyrido[2,3-d]pyrimidine-2,4,7-trione 
• 92978-47-7 3,8-Dimethyl-6-{phenyl-[(E)-(R)-1-phenyl-ethylimino]-methyl}-1H,8H-pyrido[2,3-d]pyrimidine-2,4,7-trione 
• 92978-37-5 6-benzoyl-1,2,3,4,7,8-hexahydro-3,8-dimethyl-2,4,7-trioxopyrido<2,3-d>pyrimidine 
• 92978-45-5 6-{1-[(2,4-Dinitro-phenyl)-hydrazono]-ethyl}-3,8-dimethyl-1H,8H-pyrido[2,3-d]pyrimidine-2,4,7-trione 
• 736137-02-3 3,8-dimethyl-6-(N-(R)-phenylethylcarbamoyl)-7-phenylpyrido[2,3-d]pyrimidine-2,4(3H,8H)-dione 
• 85103-24-8 3,8-Dimethyl-2,4-dioxo-7-phenyl-2,3,4,8-tetrahydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid 
• 85103-14-6 ethyl 2,3,4,8-tetrahydro-3-methyl-2,4-dioxopyrido-7-phenyl-8-methyl<2,3-d>pirimidine-6-carboxylate 
• 75427-52-0 3,10-Dimethyl-8-hydroxy-2,4(3H,10H)-pyrimido<4,5-b>chinolindion 
• 5770-19-4 5-Nitroso-4-methylamino-1-methyl-uracil 
• 75427-38-2 C₂₀H₂₄N₆O₄ 
• 75427-36-0 C₁₉H₂₀Cl₂N₆O₄ 
• 98629-74-4 5,5'-<4'-nitro-1,1'-biphenyl>-4-ylmethylenebis(6-methylamino-3-methyluracil) 
• 85103-12-4 3,6,8-Trimethyl-7-phenyl-8H-pyrido[2,3-d]pyrimidine-2,4-dione 
• 98629-73-3 5,5'-<1,1'-biphenyl>-4-ylmethylenebis(6-methylamino-3-methyluracil) 

Relevant articles and documents

Synthesis, biological active molecular design, and molecular docking study of novel deazaflavin-cholestane hybrid compounds

Novel deazaflavin-cholestane hybrid compounds, 3′,8′-disubstituted-5′-deazacholest-2,4-dieno[2,3-g]pteridine-2′,4′(3′H,8′H)-diones, have been synthesized by condensation reaction between 6-(monosubstituted amino)-pyrimidin-2,4(1H,3H)-diones and 2-hydroxymethylenecholest-4-en-3-one in presence of p-toluenesulfonic acid monohydrate and diphenyl ether. The antitumor activities against human tumor cell lines (CCRF-HSB-2 and KB cells) have been investigated in vitro, and many of these compounds showed promising antitumor activities. Furthermore, molecular docking study using LigandFit within the software package Discovery Studio 1.7 was done for lead optimization of these compounds as potential PTK inhibitors. In general, all of the synthesized steroid-hybrid compounds showed good binding affinities into PTK (PDB code: 1t46).

Autorecycling Oxidation of Alcohols Catalysed by Pyridopyrimidines as an NAD(P)(1+) Model

Two kinds of pyridopyrimidines as new NAD-type redox catalysts, 3,7,10-trisubstituted pyridodipyrimidine-2,4,6,8(1H,3H,7H,10H)-tetraones 6 and 3,8,10-trisubstituted pyridodipyrimidine-2,4,6(3H,7H,10H)-triones 7, have been synthesized by the condensation of 6-(substituted-amino)uracils 9 and 6-(substituted-amino)-2-phenylpyrimidin-4(3H)-ones 11 with appropriate 6-chloro-5-formyluracils 12 or 2,4,6-trichloropyrimidine-5-carbaldehyde 13 in dimethylformamide (DMF) or acetic acid.Compounds 6 and 7 have been found to oxidize a variety of alcohols under neutral conditions (in the absence of base) to yield the corresponding carbonyl compounds, catalytically with a markedly high turnover number.The oxidation yields were promoted remarkably depending upon the presence of lipophilic substituents, particularly due to the presence of longer alkyl groups at the 10-position.These catalysts are so stable that the oxidation reaction proceeds until the substrate is exhausted.